0
DBV Technologies S.A. Banner Image

DBV Technologies S.A.

  • Ticker DBVT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developingMore Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.
REPORT RATINGS
4.8 / 5.0 (148)

DBV Technologies S.A. reports have an aggregate usefulness score of 4.8 based on 148 reviews.

DBV Technologies S.A.

Most Recent Annual Report

DBV Technologies S.A.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!